newsfilter
← Latest News
GlobeNewswire·

ChemoCentryx Reports First Quarter 2022 Financial Results and Recent Highlights

-- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique